Zobrazeno 1 - 10
of 54
pro vyhledávání: '"TAKAKO KAMIO"'
Autor:
Mako Nogami, Takako Kamio, Takahiro Okamoto, Masako Tamaki, Hiroko Itagaki, Yoji Nagashima, Noriko Kojimahara
Publikováno v:
Tokyo Women's Medical University Journal, Vol 5, Iss 0, Pp 72-83 (2021)
Background: We evaluated 12 biomarkers as potential prognostic predictors in Japanese breast cancer patients: EGFR, PTEN, IGF-1R, Bcl-2, c-Kit, c-Met, HIF-1α, PDGFRA, survivin, VEGFR2, VEGF-A, and Ki67. Methods: A total of 466 surgical patients were
Externí odkaz:
https://doaj.org/article/f196b238b44b42b3a24c384c1d1441b7
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 52:101-105
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51753b6232d9d52c8e3a6f26c2c0d657
https://doi.org/10.3999/jscpt.52.101
https://doi.org/10.3999/jscpt.52.101
Autor:
Hiroyasu, Yamashiro, Hiroji, Iwata, Norikazu, Masuda, Naohito, Yamamoto, Reiki, Nishimura, Shoichiro, Ohtani, Nobuaki, Sato, Masato, Takahashi, Takako, Kamio, Kosuke, Yamazaki, Tsuyoshi, Saito, Makoto, Kato, Tecchuu, Lee, Katsumasa, Kuroi, Toshimi, Takano, Shinji, Yasuno, Satoshi, Morita, Shinji, Ohno, Masakazu, Toi, Y, Tokunaga
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background Previous large trials of trastuzumab (TZM) demonstrated improved outcomes in patients with HER2-positive early breast cancer. However, its effectiveness and safety in Japanese patients is not yet clear. Recently, new anti-HER2 agents were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ab8074fe03ca51825b22989b4dd2da
https://doi.org/10.1007/s12282-020-01057-4
https://doi.org/10.1007/s12282-020-01057-4
Autor:
Hidenori Kamio, Hitoshi Kanno, Toshitaka Uchiyama, Shingo Kameoka, Kayoko Saito, Takako Kamio, Takahiro Okamoto, Yoshiko Onoe
Publikováno v:
Pharmacogenomics. 20:353-365
Aim: The aim of this study was to identify pharmacogenomic biomarkers to predict tegafur–uracil (UFT)-induced liver dysfunction. Patients & methods: A total of 68 patients, who were administered UFT, were evaluated using a two-step pharmacogenomics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d68c226476ea44676ff4f1d63ffab41
https://doi.org/10.2217/pgs-2018-0100
https://doi.org/10.2217/pgs-2018-0100
Autor:
Yumiko Ondo, Hitoshi Kanno, Takako Aoki, Toshiyuki Yamamoto, Takako Kamio, Takahiro Okamoto, Motoko Watanabe, Hidenori Kamio, Keiko Yamamoto-Shimojima, Tomoki Uchiyama
Publikováno v:
Anticancer research. 40(8)
Background/aim Historically, breast cancer has been treated according to an evaluation of biomarkers, such as the estrogen receptor and HER2 status. Recently, molecular profiling has been used to detect driver mutations and select anti-cancer treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edda7979888bcf74ffa03166014d4434
https://pubmed.ncbi.nlm.nih.gov/32727787
https://pubmed.ncbi.nlm.nih.gov/32727787
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 79:294-301
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2824ab6c82fb63280469866c6a271523
https://doi.org/10.3919/jjsa.79.294
https://doi.org/10.3919/jjsa.79.294
Autor:
Takako Kamio, Kunio Kawanishi, Hideaki Oda, Eiichiro Noguchi, Shingo Kameoka, Tomoko Yamamoto, Tetsuya Ohchi, Yoji Nagashima, Hiroko Itagaki, Atsuko Hiroi
Publikováno v:
Oncology Letters. 13:1714-1718
Synchronous bilateral breast cancer is rare, and oncocytic carcinoma is an even rarer breast cancer histological subtype. In general, oncocytic tumors are defined as neoplasms with eosinophilic granular cytoplasm and have been reported in various org
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a249636bb84464fdd4f712a0dd874134
https://doi.org/10.3892/ol.2017.5610
https://doi.org/10.3892/ol.2017.5610
Autor:
Hidenori, Kamio, Toshitaka, Uchiyama, Hitoshi, Kanno, Yoshiko, Onoe, Kayoko, Saito, Shingo, Kameoka, Takako, Kamio, Takahiro, Okamoto
Publikováno v:
Pharmacogenomics. 20(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aa17dfdb8eec3be28f585cfcd8abc0df
https://pubmed.ncbi.nlm.nih.gov/30734632
https://pubmed.ncbi.nlm.nih.gov/30734632
Autor:
MAMIKO UBUKATA1, TAKAKO KAMIO1 ako@surg2.twmu.ac.jp, TETSUYA OHCHI1, EIICHIRO NOGUCHI1, HIROKO TSUKADA1, SHINGO KAMEOKA1
Publikováno v:
Oncology Letters. May2016, Vol. 11 Issue 5, p3071-3074. 4p.
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 77:2417-2423
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c1328e1047fd0427886a1feab405214
https://doi.org/10.3919/jjsa.77.2417
https://doi.org/10.3919/jjsa.77.2417